No Data
First Pharmaceutical Holdings (Beijing) Co., Ltd. 2024 Annual Results Report
Shouyao Holdings (688197.SH): Net loss of 0.2 billion yuan in 2024.
On January 17, Gelonghui reported that Shouyao Holdings (688197.SH) announced its 2024 annual performance report. During the reporting period, the company achieved total operating revenue of 3.942 million yuan, with research and development expenses of 211.3374 million yuan; the net income attributable to parent company owners was -201.0638 million yuan, and the net income attributable to parent company owners after deducting non-recurring gains and losses was -224.0882 million yuan. As of the end of the reporting period, the company's total assets were 933.123 million yuan, and the equity attributable to parent company owners was 819.8883 million yuan.
Vopar Pharmaceuticals (688197.SH): Adjusting the development strategy of the BTK inhibitor SY-1530.
Gelonghui, November 6th | Shouyao Holdings (688197.SH) announced that as of now, multiple BTK inhibitors have been approved for marketing globally, with 5 drugs approved for marketing domestically, and multiple pipelines in clinical research stage. The company has carefully evaluated the market competition landscape, development progress, expected scale of investment in future registration clinical trials, future market share, and commercial returns of the candidate drug SY-1530, and decided to adjust the follow-up development strategy of SY-1530 taking into account the manpower, material resources, and funding requirements for key clinical trials and registration applications of other core candidate drugs.
First Pharmaceutical Holdings (Beijing) Co., Ltd. Report for the Third Quarter of 2024
Shuoyao Holdings (688197.SH): The new drug application for the ALK inhibitor cantaanib granules (CT-707) has been accepted.
On October 22, GeLongHui announced that Shouyao Holdings (688197.SH) recently received the "Acceptance Letter" issued by the National Medical Products Administration. The company's independently developed Kangtai tinib granules (CT-707, applied commodity name: Shouyaoze) as a single drug is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positive new drug listing application (NDA) has been accepted.
Shouyao Holdings: Summary of the semi-annual report of Shouyao Holdings (Peking) Co., Ltd. in 2024
